Individual operating biotechnology corporations like Aldeyra Therapeutics (ALDX) do not track or report a Net Asset Value (NAV) per share in the manner typical of mutual funds or exchange-traded funds, because operating firms do not hold a static basket of external securities. Instead, financial analysts evaluate the company's valuation through its market capitalization (hovering around $93 million to $95 million USD), total cash reserves, enterprise value, and per-share equity metrics.